Granite Investment Partners LLC grew its stake in Horizon Therapeutics PLC (NASDAQ:HZNP) by 22.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 57,219 shares of the biopharmaceutical company’s stock after buying an additional 10,401 shares during the period. Granite Investment Partners LLC’s holdings in Horizon Therapeutics were worth $1,512,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. Strs Ohio grew its holdings in Horizon Therapeutics by 58.9% during the fourth quarter. Strs Ohio now owns 20,500 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 7,600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Horizon Therapeutics by 10.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,271 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 1,149 shares during the last quarter. D.A. Davidson & CO. grew its holdings in Horizon Therapeutics by 5.1% during the fourth quarter. D.A. Davidson & CO. now owns 10,592 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 512 shares during the last quarter. Keybank National Association OH acquired a new position in Horizon Therapeutics during the fourth quarter valued at approximately $209,000. Finally, Rhumbline Advisers grew its holdings in Horizon Therapeutics by 45.9% during the fourth quarter. Rhumbline Advisers now owns 238,785 shares of the biopharmaceutical company’s stock valued at $4,666,000 after purchasing an additional 75,099 shares during the last quarter. 87.79% of the stock is owned by institutional investors.
HZNP has been the topic of several analyst reports. Piper Jaffray Companies set a $33.00 price target on Horizon Therapeutics and gave the company a “buy” rating in a report on Thursday, April 4th. Cantor Fitzgerald increased their price target on Horizon Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. BidaskClub downgraded Horizon Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 20th. Jefferies Financial Group increased their price target on Horizon Therapeutics to $34.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, Cowen set a $33.00 price objective on shares of Horizon Therapeutics and gave the stock a “buy” rating in a research note on Thursday, February 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $30.83.
Shares of Horizon Therapeutics stock traded down $0.06 during midday trading on Wednesday, hitting $23.21. The company had a trading volume of 21,453 shares, compared to its average volume of 1,757,441. The company has a market cap of $4.28 billion, a price-to-earnings ratio of 12.66 and a beta of 0.92. The company has a current ratio of 1.74, a quick ratio of 1.68 and a debt-to-equity ratio of 0.90. Horizon Therapeutics PLC has a 1-year low of $15.92 and a 1-year high of $29.44.
Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.20. The business had revenue of $280.00 million for the quarter, compared to the consensus estimate of $238.35 million. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. Horizon Therapeutics’s quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter last year, the company posted $0.03 earnings per share. As a group, research analysts forecast that Horizon Therapeutics PLC will post 1.63 earnings per share for the current fiscal year.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.